Expression Table for this CRE
| CNhs14417 | 293SLAM rinderpest infection, 24hr, biol_rep2 | 14.0 |
| CNhs13844 | iPS differentiation to neuron, down-syndrome donor C11-CCL54, day06, rep2 | 12.5 |
| CNhs14078 | amygdala, newborn, donor10223 | 6.3 |
| CNhs13841 | iPS differentiation to neuron, control donor C32-CRL1502, day12, rep2 | 3.3 |
| CNhs13831 | iPS differentiation to neuron, down-syndrome donor C11-CCL54, day06, rep1 | 2.4 |
| CNhs13837 | iPS differentiation to neuron, down-syndrome donor C18-CCL54, day12, rep1 | 2.2 |
| CNhs13845 | iPS differentiation to neuron, down-syndrome donor C11-CCL54, day12, rep2 | 2.2 |
| CNhs13833 | iPS differentiation to neuron, down-syndrome donor C11-CCL54, day18, rep1 | 1.9 |
| CNhs12698 | K562 erythroblastic leukemia response to hemin, 12hr, biol_rep2 | 1.8 |
| CNhs14490 | ARPE-19 EMT induced with TGF-beta and TNF-alpha, 02hr30min, biol_rep3 | 1.8 |
| SRX6586336 | CNhi10317_MCF-7_Rosuvastatin-30 uM-6h_rep1 | 1.7 |
| SRX6586337 | CNhi10317_MCF-7_Rosuvastatin-30 uM-6h_rep2 | 1.5 |
| CNhs12311 | amygdala, adult, donor10252 | 1.4 |
| CNhs13332 | Monocyte-derived macrophages response to LPS, 20hr, donor3 (t22 Subject3) | 1.3 |
| CNhs14060 | iPS differentiation to neuron, down-syndrome donor C18-CCL54, day00, rep2 | 1.3 |
| CNhs13840 | iPS differentiation to neuron, control donor C32-CRL1502, day06, rep2 | 1.0 |
| SRX6586357 | CNhi10330_MCF-7_siRNA-negative control-48h_rep5 | 1.0 |
| CNhs11844 | acantholytic squamous carcinoma cell line:HCC1806 | 0.9 |
| SRX6586360 | CNhi10331_MCF-7_siRNA (HSS104864) treatment-48h_rep3 | 0.9 |
| SRX6586343 | CNhi10318_MCF-7_Simvastatin-30 uM-48h_rep1 | 0.8 |
| CNhs12860 | Saos-2 osteosarcoma treated with ascorbic acid and BGP to induce calcification, 00hr15min, biol_rep2 (A2 T1) | 0.8 |
| SRX6586351 | CNhi10319_MCF-7_Rosuvastatin-30 uM-48h_rep3 | 0.8 |
| SRX9760367 | skeletal muscle_1_h_after_exercise (Individual 4) | 0.8 |
| SRX6586348 | CNhi10319_MCF-7_Fluvastatin-30 uM-48h_rep3 | 0.7 |
| SRX6586353 | CNhi10330_MCF-7_siRNA-negative control-48h_rep1 | 0.7 |
| CNhs14496 | ARPE-19 EMT induced with TGF-beta and TNF-alpha, 03hr30min, biol_rep3 | 0.7 |
| SRX6586362 | CNhi10331_MCF-7_siRNA (HSS179267) treatment-48h_rep2 | 0.7 |
| CNhs12052 | Fibroblast - Dermal, donor4 | 0.7 |
| CNhs14472 | ARPE-19 EMT induced with TGF-beta and TNF-alpha, 00hr45min, biol_rep1 | 0.7 |
| CNhs12054 | Bronchial Epithelial Cell, donor4 | 0.7 |
| CNhs12017 | Adipocyte - subcutaneous, donor3 | 0.6 |
| CNhs11982 | Preadipocyte - visceral, donor2 | 0.6 |
| SRX6586349 | CNhi10319_MCF-7_Rosuvastatin-30 uM-48h_rep1 | 0.5 |
| CNhs12660 | MCF7 breast cancer cell line response to HRG, 03hr00min, biol_rep2 | 0.5 |
| CNhs13362 | Aortic smooth muscle cell response to FGF2, 01hr, biol_rep2 (LK14) | 0.5 |
| CNhs13338 | mesenchymal stem cells (adipose derived), adipogenic induction, day14, biol_rep1 | 0.5 |
| CNhs13344 | Aortic smooth muscle cell response to FGF2, 02hr, biol_rep1 (LK16) | 0.5 |
| SRX9760358 | skeletal muscle_3_h_after_exercise (Individual 2) | 0.5 |
| SRX6586344 | CNhi10318_MCF-7_Simvastatin-30 uM-48h_rep2 | 0.5 |
| CNhs13581 | Aortic smooth muscle cell response to IL1b, 01hr, biol_rep3 (LK45) | 0.5 |
| SRX6586352 | CNhi10330_MCF-7_siRNA (HSS104864) treatment-48h_rep1 | 0.5 |
| SRX4504726 | human CAGE MCF-7, response to HRG, 120 min, biol_rep3 | 0.5 |
| CNhs14580 | Myoblast differentiation to myotubes, day03, control donor3 | 0.5 |
| CNhs12740 | MCF7 breast cancer cell line response to HRG, 08hr, biol_rep1 | 0.5 |
| SRX6586359 | CNhi10331_MCF-7_siRNA (HSS104864) treatment-48h_rep2 | 0.5 |
| SRX6586358 | CNhi10330_MCF-7_siRNA-negative control-48h_rep6 | 0.4 |
| CNhs13145 | Monocyte-derived macrophages response to LPS, 00hr15min, donor1 (t2 Subject1) | 0.4 |
| SRX6586346 | CNhi10319_MCF-7_Fluvastatin-30 uM-48h_rep1 | 0.4 |
| SRX6586342 | CNhi10318_MCF-7_Non-treatment (DMSO)-48h_rep6 | 0.4 |
| CNhs14485 | ARPE-19 EMT induced with TGF-beta and TNF-alpha, 02hr00min, biol_rep1 | 0.4 |